Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study

BackgroundExtensive-stage small cell lung cancer (ES-SCLC) has a poor prognosis, with historical median overall survival (OS) of 8–13 months under platinum-etoposide chemotherapy. While phase III trials established adebrelimab (anti-PD-L1) plus chemotherapy as a new standard, real-world evidence rem...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kaili Xu, Jian Wang, Zhenhe Weng, Junhui Wang, Jianxin Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-10-01
coleção:	Frontiers in Immunology
Assuntos:	adebrelimab extensive-stage small cell lung cancer real-world study first-line therapy prognostic factors
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1678020/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!